Corona Remedies Ltd., a Gujarat-based pharmaceutical company, has officially launched its much-anticipated ₹655 crore IPO on December 8, 2025, structured entirely as an Offer for Sale (OFS). With a price band of ₹1,008–₹1,062, the IPO has attracted considerable investor attention due to the company’s strong financial track record, diversified product portfolio, and stable demand outlook in the Indian pharmaceutical market.
On the very first day, the IPO witnessed a 27% overall subscription, highlighted by 41% retail participation, signaling strong interest among individual investors. Early momentum is supported by a Grey Market Premium (GMP) of ₹290, indicating a potential 27% listing gain if market conditions remain steady by the listing date.
As the broader market continues to reward niche, specialty pharma players, Corona Remedies has carved out an interesting position—well-established in chronic therapies but still small enough to enjoy meaningful scalability. With investors actively tracking IPO-linked opportunities in December, this issue stands out due to its financial stability, predictable revenue streams, and improving profitability.
Company Overview
Corona Remedies Ltd. is a 2004-founded pharmaceutical manufacturer and marketer headquartered in Ahmedabad, Gujarat. Over the last two decades, the company has steadily evolved from a mid-tier pharma player into a nationally recognized brand with a presence across several high-demand therapeutic categories.
Therapeutic Focus
The company’s product basket spans:
- Anti-infectives
- Cardiology
- Gastroenterology
- Pain management
- Anti-diabetic formulations
- Respiratory medicines
- Gynecology & dermatology
This balanced therapeutic spread reduces dependency risk and helps stabilize revenues, especially during volatile regulatory cycles. Corona Remedies operates manufacturing facilities with WHO-GMP and regulatory approvals, enabling it to supply both domestic and select international markets.
Financial Growth
Corona Remedies has posted consistent revenue and profit expansion:
- FY23 Revenue: ₹891 crore
- FY24 Revenue: ₹1,021 crore
- FY25 Revenue: ₹1,202 crore
- FY25 Profit After Tax (PAT): ₹149 crore
This growth trajectory reflects:
- The rising demand for branded generics
- Scale expansion in chronic treatment segments
- Efficient distribution networks reaching Tier-2 and Tier-3 cities
Among the most notable aspects is the company’s improving profitability. PAT growth has outpaced revenue growth, thanks to better cost management, product mix improvement, and declining borrowings.
For readers new to IPO structures, especially Offer for Sale, refer to our detailed guide on What is OFS to understand how existing shareholders monetize their stakes without bringing new capital into the business.
IPO Timeline and Key Details
Corona Remedies IPO follows a tight and investor-friendly schedule, aligned with recent market norms. Here are the key dates and details:
- IPO Opens: December 8, 2025
- IPO Closes: December 10, 2025
- Basis of Allotment: December 11, 2025
- Refunds/Unblock of Funds: December 12, 2025
- Credit to Demat Accounts: December 13–14, 2025
- Listing Date (BSE/NSE): December 15, 2025
- Anchor Investor Bidding: Closed on December 5, 2025
Lot Size
- Lot Size: 14 shares
- Minimum Retail Investment:
14 shares × ₹1,062 (upper band) = ₹14,868
This lower entry barrier makes it appealing to retail investors seeking either short-term listing gains or long-term exposure to the pharma sector.
IPO Detail Table
| Detail | Information |
|---|---|
| Issue Size | ₹655.37 crore (OFS) |
| Price Band | ₹1,008 – ₹1,062 |
| Lot Size | 14 shares |
| Allotment Date | December 11, 2025 |
| Listing Date | December 15, 2025 |
GMP Today: What It Means for Investors
The Grey Market Premium (GMP) acts as an unofficial indicator of how an IPO might perform on the listing day. While not regulated, it is widely tracked by traders and analysts due to its correlation with market sentiment.
Current GMP (as of today): ₹290
This implies:
- 27.31% premium over the upper price band of ₹1,062
- Estimated listing price: Approximately ₹1,352 per share
Before the IPO opened, GMP was trading around 34%, which means sentiment has cooled slightly but remains strongly positive.
Why GMP Matters
- Indicates early demand from the unlisted market
- Helps investors predict listing gains
- Reflects market sentiment toward the sector (pharma currently enjoys moderate bullishness)
If you want to understand how GMP works, refer to our simplified GMP Explainer Guide.
Subscription Status Update
On Day 1, Corona Remedies IPO saw moderate but promising subscription figures:
- Overall: 27%
- Retail: 41%
- NII (High Net-worth Individuals): Subdued but expected to rise on Day 2–3
- QIB (Institutional Investors): Typically bid on the last day
What the Numbers Mean
Retail participation outpacing other categories suggests:
- Brand recall among pharmacy customers
- Trust in pharma IPOs
- Lower ticket sizes encouraging mass participation
Platforms such as NSE, BSE, and Bigshare Services (the registrar for the issue) provide real-time updates for investors tracking allotment probability.
If you want to dive deeper into allotments and probability calculations, check our IPO Allotment Guide for step-by-step clarity.
Financial Highlights and Growth Story
Corona Remedies has demonstrated consistent growth supported by strong fundamentals. Here’s a detailed look:
Revenue Growth
- FY23: ₹891 crore
- FY24: ₹1,021 crore
- FY25: ₹1,202 crore
This 35% growth over two years is significant for a mid-cap pharmaceutical company operating in a competitive generics market.
Profitability
- FY25 PAT: ₹149 crore
- EBITDA: ₹246 crore
- EBITDA Margin: ~20.5%, healthy for branded generics
Balance Sheet Strength
- Borrowings: Reduced to ₹63 crore
- Net Worth: Strong at ₹606 crore
Lower debt enhances resilience and boosts valuation attractiveness. Pharma businesses benefit from strong balance sheets due to:
- Long R&D cycles
- Inventory-heavy manufacturing processes
- Regulatory compliance expenses
Corona Remedies seems firmly positioned to handle these efficiently.
Growth Drivers
- Scaling established therapies (cardiology, diabetes)
- Expanding presence in high-growth Tier-2/3 markets
- Increasing brand penetration through medical representatives
- Leveraging digital healthcare platforms for distribution
- Focusing on chronic segments which offer longer prescription cycles
Risks to Consider
No investment is risk-free. Some challenges include:
- Pharmacy price controls under the National List of Essential Medicines (NLEM)
- High competition from established brands
- Regulatory inspections and compliance requirements
- Margin pressures due to rising raw material imports
However, the company’s multi-therapy approach and financial discipline make it a balanced option for investors.
Risks and Investment Considerations
Before applying for the IPO, investors should weigh the pros and cons carefully.
Why Some Investors Are Bullish
- Strong financial growth
- Healthy GMP indicating listing pop potential
- Brand visibility in chronic therapies
- Low debt levels improving future expansion plans
- Consistent PAT performance, rare among mid-cap pharma players
Why Some Investors Might Stay Cautious
- Entirely an OFS—meaning no new funds go into the company
- Regulatory uncertainties remain high in pharma
- Promoter dilution may raise questions about long-term strategy
- Listing gains may shrink if market volatility intensifies
Who Should Subscribe?
Good Fit For:
- Retail investors seeking moderate listing gains
- Long-term investors betting on pharma stability
- Investors preferring companies with strong fundamentals and low leverage
Not Ideal For:
- Those seeking explosive, high-growth biotech plays
- Investors wanting fresh capital deployment instead of OFS
- Traders who dislike moderate GMP fluctuations
Diversification remains key. Platforms like Acumen Capital Market offer broader pharma sector portfolios for risk balancing.
Key Takeaways
- GMP Today: ₹290 (≈27% premium); expected listing near ₹1,352
- Subscription Status: 27% overall on Day 1; retail at 41%
- Financial Snapshot: FY25 revenue at ₹1,202 crore; PAT at ₹149 crore
- IPO Dates: Open till December 10; allotment on Dec 11; listing on Dec 15
- OFS Structure: Existing shareholders offloading stake—no new capital infused
Corona Remedies IPO delivers a compelling mix of strong fundamentals, steady market demand, and favorable GMP sentiment. While not a blockbuster issue, it aligns well with investors seeking stability and reasonable listing gains.
FAQ
1. What is Corona Remedies IPO GMP today?
GMP stands at ₹290, suggesting around 27% upside over the upper price band.
2. When does subscription end?
The IPO closes on December 10, 2025.
3. How do I apply for Corona Remedies IPO?
Apply via:
- ASBA through your bank
- UPI applications via brokers like Acumen Capital
Minimum investment: 14 shares × price band.
4. Is there listing gain potential?
GMP signals a strong debut, but listing gains are always market-linked and not guaranteed.
